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A BLOC-1 Mutation Screen Reveals that PLDN
Is Mutated in Hermansky-Pudlak Syndrome Type 9
Andrew R. Cullinane,1,* James A. Curry,1 Carmelo Carmona-Rivera,1 C. Gail Summers,2 Carla Ciccone,1
Nicholas D. Cardillo,1 Heidi Dorward,1 Richard A. Hess,1 James G. White,3 David Adams,1,4
Marjan Huizing,1 and William A. Gahl1,4
Hermansky-Pudlak Syndrome (HPS) is an autosomal-recessive condition characterized by oculocutaneous albinism and a bleeding diath-
esis due to absent platelet delta granules. HPS is a genetically heterogeneous disorder of intracellular vesicle biogenesis. We first screened
all our patients with HPS-like symptoms for mutations in the genes responsible for HPS-1 through HPS-6 and found no functional muta-
tions in 38 individuals. We then examined all eight genes encoding the biogenesis of lysosome-related organelles complex-1, or BLOC-1,
proteins in these individuals. This identified a homozygous nonsense mutation in PLDN in a boy with characteristic features of HPS.
PLDN is mutated in the HPS mouse model pallid and encodes the protein pallidin, which interacts with the early endosomal t-SNARE
syntaxin-13.We could not detect any full-length pallidin in our patient’s cells despite normalmRNA expression of themutant transcript.
We could detect an alternative transcript that would skip the exon that harbored themutation, but we demonstrate that if this transcript
is translated into protein, although it correctly localizes to early endosomes, it does not interact with syntaxin-13. In our patient’s mela-
nocytes, the melanogenic protein TYRP1 showed aberrant localization, an increase in plasma-membrane trafficking, and a failure to
reach melanosomes, explaining the boy’s severe albinism and establishing his diagnosis as HPS-9.Introduction
Hermansky-Pudlak Syndrome (HPS; MIM 203300) is a rare
autosomal-recessive condition characterized by reduced
skin, hair, and eye pigmentation and a bleeding diathesis
due to absent platelet delta granules. Occasionally, HPS
patients are found to have additional symptoms, including
pulmonary fibrosis, granulomatous colitis, and immuno-
deficiency.1 To date, eight HPS subtypes (HPS1–8; MIM
604982, 608233, 606118, 606682, 607521, 607522,
607145, and 609762) and genes have been identified in
humans;2–8 their protein products are involved in the
biogenesis of lysosome-related organelles such as melano-
somes in melanocytes and delta granules in plate-
lets.1,9,10 All known HPS proteins are components of one
of four protein complexes: BLOC-1, BLOC-2, BLOC-3, or
Adaptor Protein Complex-3 (AP-3).
BLOC-1 contains eight subunits: BLOC1S1, BLOC1S2,
BLOC1S3 (HPS8), cappuccino, dysbindin (HPS7), muted,
pallidin, and snapin (MIM 601444, 609768, 609762,
605695, 607145, 607289, 604310, and 607007, respec-
tively). HPS mouse models exist for mutations in five of
the eight BLOC-1 subunits.11 Relatively little is known
about the exact subcellular function of the BLOC-1 com-
plex constituents. However, interaction of the snapin sub-
unit with the t-SNARE SNAP25 suggests a role in synapse
function in neuronal tissues. In nonneuronal tissue, sna-
pin interacts with the SNAP25 counterpart, SNAP23,12
and the pallidin subunit interacts with the early endoso-
mal t-SNARE Syntaxin-13;13 both interactions suggest
a role in endosomal protein sorting.1Medical Genetics Branch, National Human Genome Research Institute, Na
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known.7,8 Specifically, HPS-7 and HPS-8 involve mutations
in dysbindin and BLOC1S3, respectively. In the current
study, we screened patients with clinical findings sugges-
tive of HPS for mutations in additional BLOC-1 subunits
and identified a single individual with a mutation in the
PLDN gene encoding the pallidin subunit of BLOC-1,
and these findings define the HPS-9 subtype.Material and Methods
Patients
All 38 patients were enrolled in either clinical protocol
NCT00001456 ‘‘Clinical and Basic Investigations into Herman-
sky-Pudlak Syndrome,’’ or protocol NCT00369421, ‘‘Diagnosis
and Treatment of Inborn Errors of Metabolism and Other Genetic
Disorders,’’ approved by the NHGRI Institutional Review Board.
All patients or their parents provided written, informed consent.
The HPS-9 patient was enrolled in protocol NCT00369421, and
written, informed consent was obtained from his parents.
Tissue Culture
Primary patient and control fibroblasts and melanocytes were
cultured from a forearm skin biopsy. Fibroblasts were grown in
high-glucose (4.5 g/liter) DMEM medium supplemented with
10% fetal calf serum (FCS; Gemini Bio-Products, West Sacramento,
CA), 2 mM L-glutamine, MEM nonessential amino acid solution,
and penicillin-streptomycin. Melanocytes were cultured in
Ham’s F10 (Invitrogen, Carlsbad, CA), supplemented with 5%
FCS, 5 mg/liter basic fibroblast growth factor (Sigma, St. Louis,
MO), 10 mg/liter endothelin (Sigma), 7.5 mg/liter 3-isobutyl-1-
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3.3 mg/liter phorbol 12-myristate 13-acetate (Sigma), 10 ml pen/
strep/glutamine (Invitrogen) and 1 ml fungizone (Invitrogen).
Melanocytes were transfected with 1 mg of cDNA constructs via
the Amaxa nucleofection system (Lonza, Walkersville, MD).gDNA Analysis: Sequencing and SNP Array
For gDNA sequencing of BLOC-1 subunits, we designed primers
to cover all coding exons and flanking intronic regions of
BLOC1S1 (NT_029419.12), BLOC1S2 (NT_030059.13), BLOC1S3
(NT_011109.16), CNO (NT_006051.18), DTNBP1 (NT_007592.15),
MUTED (NT_007592.15), PLDN (NT_010194.17), and SNAPIN
(NT_004487.19); primer sequences are shown in Table S1, available
online. Direct sequencing was carried out with the di-deoxy termi-
nation method (ABI BigDye Terminator v3.1) on an ABI 3130xl
DNA sequencer (Applied Biosystems, Austin, TX). Results were
analyzedwith Sequencher v4.9 software (Gene Codes Corporation,
AnnArbor, MI). TheHPS-9 patient’s mutation in PLDNwas verified
bidirectionally and based on the accession number NM_012388.2.
For SNP genotyping, genomic DNA was run on a Human 1M-Duo
DNA Analysis BeadChip, and the data were analyzed with the
GenomeStudio software (both from Illumina, San Diego, CA).RNA Analysis: Extraction, cDNA, and qRT-PCR
Total RNA was isolated from control and patient fibroblasts and
melanocytes with the RNA-Easy Mini-Kit (QIAGEN) according to
the manufacturer’s protocol. RNA was treated with a DNase kit
(DNA-free) according to the manufacturer’s protocol (Applied
Biosystems, Austin, TX) so that all remaining DNA could be
removed. RNA concentrations and purity were measured on the
NanodropND-1000 apparatus (Nanodrop Technologies,Wilming-
ton, DE). First-strand cDNA was synthesized with a high-capacity
RNA-to-cDNA kit (Applied Biosystems) according to the manufac-
turer’s guidelines. Human and fetal cDNA panels were purchased
from Promega (Madison, WI). For tissue-specific cDNA expression
studies (Figure 3B), primers specific to each PLDN transcript (tran-
script 1, PLDN1,NM_012388.2—forward primer across exon 3 and
4 boundary and reverse primer within exon 5; transcript 2, PLDN2,
AK128626—forward primer in exon A and reverse primer across
exon 2 and exon B boundary) and GAPDH (NM_002046.3) were
designed and used for standard polymerase chain reaction (PCR)
(primer sequences are shown in Table S2). For patient and control
fibroblast and melanocyte cDNA analysis (Figure 3C), primers
amplifying exclusively the entire coding region of either PLDN1
or PLDN2 were used. All PCR products were electrophoresed
on 2% agarose gels. For quantitative real-time PCR (qRT-PCR),
Taqman gene expression master mix reagent and Assays-On-
Demand (Applied Biosystems) were obtained for PLDN (assay
IDs Hs00202626_m1 and Hs01126975_m1) and a control gene,
GAPDH (assay ID Hs99999905_m1). qRT-PCR was performed
with 100 ng cDNA on an ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems) by the comparative CT method
(DDCT); this method measures relative gene expression.
14 The
cycling conditions were as follows: 2 min at 50C, 10 min at
95C, and 40 cycles at 95C for 15 s and 60C for 60 s.Plasmids
For cDNA constructs, forward and reverse primers were designed
to include the native translation initiation (ATG) and termination
codons, allowing ligation into the pCMV-Myc tag (C-terminal)
expression vector (Clontech, Mountain View, CA) with EcoR1
and KpnI (50 and 30, respectively). Primer sequences are shownThe Amein Table S3. A full-length PLDN IMAGE cDNA clone (3450397)
was purchased from Thermo Scientific (Waltham, MA), and the
PLDN-D3 transcript was amplified from patient cDNA.
Antibodies
Mousemonoclonal antibodies against the following proteins were
acquired as follows: syntaxin-13 (used for immunoblotting; clone
15G12, Abcam, Cambridge MA), Myc-tag (clone 9E10), b-actin
(Clone AC-15), a-tubulin (clone B-5-1-2; all from Sigma Aldrich,
St. Louis MO), TYRP1 (used for immunofluorescence and internal-
ization assays; clone TA99, ATCC, Masasses VA), tyrosinase (clone
T311, Santa Cruz Biotechnology, Santa Cruz, CA), and cappuccino
(clone S-5; Santa Cruz Biotechnology). Rabbit polyclonal anti-
bodies against the following proteins were acquired as follows:
syntaxin-13 (used for immunofluorescence; Synaptic Systems
GmbH, Goettingen Germany), PMEL-17 (Neomarkers, Fremont,
CA), TYRP1 (used for immunoblotting) and HPS4 (both from
Santa Cruz Biotechnology, Santa Cruz, CA), and HPS5 and snapin
(both from ProteinTech, Chicago, IL). A sheep polyclonal anti-
body against TGN38 was obtained from AbD Serotec (Raleigh,
NC), and a goat polyclonal antibody against EEA1 was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). The mouse
monoclonal antibody against pallidin was a kind gift from Dr. E.
Dell’Angelica (UCLA School of Medicine, Los Angeles, CA).
Protein Extraction and Immunoblotting
Cells were grown to confluency in 25 cm2 flasks, washed twice
with ice-cold PBS, and scraped into 250 ml of cell lysis buffer
containing 50 mM Tris-HCl (pH 7.5), 50 mM sodium fluoride,
5 mM sodium pyrophosphate, 1 mM sodium orthovanadate,
1 mM EDTA, 1 mM EGTA, 0.27 M sucrose, 1% Triton X-100,
and Complete, Mini Protease Inhibitor Cocktail (Roche Diagnos-
tics). Cell lysates were centrifuged (at 15,000 RPM for 15 min at
4C); supernatants were removed for immunoblotting or coim-
munoprecipitation experiments. Twenty micrograms of total
protein, as determined by the Dc Protein assay (BioRad, Hercules,
CA), were loaded onto 4%–20% Tris-Glycine gels. Proteins were
blotted onto PVDF membranes (Invitrogen) for HRP detection
or onto nitrocellulose membranes (Invitrogen) for Li-Cor detec-
tion. After blotting, membranes were probed with the appropriate
antibodies, and loading was controlled by blotting of the same
membranes with either a-tubulin or b-actin. HRP-conjugated
secondary anti-mouse or anti-rabbit antibodies (Amersham
Biosciences, Piscataway, NJ) and IRDye 800CW-conjugated
secondary anti-mouse or anti-rabbit antibodies (Li-Cor Biosci-
ences, Lincoln, NE) were used. The antigen-antibody complexes
were visualized with an Enhanced Chemiluminescence (ECL) kit
(Amersham Biosciences, Piscataway, NJ) or detected with the
Li-Cor Odyssey Infrared imaging system. All blots were detected
with HRP except for HPS5 and a-tubulin, where Li-Cor detection
was used.
Coimmunoprecipitation and Plasma-Membrane
Protein Biotinylation
For coimmunoprecipitation, 20 mg of anti-Myc monoclonal
antibodies were covalently conjugated to 100 ml of Dynabeads
Protein G (Invitrogen) with dimethyl pimelimidate and trietha-
nolamine according to the manufacturer’s instructions. Trans-
fected control melanocytes growing in T25 flasks were harvested
48 hr after transfection, and proteins were extracted as described
above. Extracted proteins (1 mg) were mixed with 20 ml ofrican Journal of Human Genetics 88, 778–787, June 10, 2011 779
antibody-conjugated Dynabeads and incubated on a blood rotor
with end-over-end mixing (at 4C for 3 hr). The complexes were
then washed three times with cell lysis buffer supplemented
with 150 mM NaCl, after which proteins were eluted by being
boiled in 23 SDS loading buffer (10 min). The protein samples
were loaded directly onto SDS-PAGE gels for immunoblotting
analysis. For membrane protein biotinylation, control and patient
melanocytes were incubated with 500 ml of 0.25 mg/ml EZ-Link
Sulfo-NHS-SS-Biotin (Thermo Scientific, Waltham, MA) for
30 min at 4C. This reaction was quenched by incubation with
1 M NH4Cl for 5 min. Protein was then extracted via the protocol
above. The biotin-labeled proteins were separated from the total
lysates with streptavidin Dynabeads (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. The protein samples
were loaded directly onto SDS-PAGE gels for immunoblotting
analysis.Immunofluorescence Microscopy
Cells were grown in four-well chamber slides, fixed with 4%
paraformaldehyde, and permeabilized with 0.1% Triton X-100.
Alexafluor 488 and 555 secondary antibody conjugates were
purchased from Invitrogen (Carlsbad, CA), and nuclei were coun-
terstained with DAPI (Vector Laboratories, Burlingame, CA). Cells
were imaged with a Zeiss 510 META confocal laser-scanning
microscope with the pinhole set to 1 Airy unit. A series of optical
sections were collected from the xy plane and merged into
maximum projection images.TYRP1 Internalization Assay
This assay was carried out essentially as previously described.15
In brief, control and HPS-9 patient melanocytes were trypsinized
and washed twice with Ham’s F10 medium containing 10%
FBS and 25 mM HEPES. For each time point, 2 3 105 cells were
used and incubated with a monoclonal antibody against TYRP1
on ice for 30 min so that antibody binding to plasma membrane
TYRP1 could take place. Cells were then washed twice with
medium and transferred to 37C for different amounts of time
(0, 5, 10, 15, 30, and 60 min), after which they were incubated
on ice with Alexafluor-488-conjugated secondary antibodies for
30 min. The cells were then washed twice withmedium and resus-
pended in FACS buffer (5% FBS, 1 mM EDTA in 13 PBS). The
samples were sorted on a Becton Dickenson FACSCalibur flow
cytometer, and the amount of green fluorescence was counted
and analyzed with FlowJo software.Results
BLOC-1 Mutation Screen
We screened 38 patients with HPS-like symptoms but no
mutations associated with HPS1–6. We completely
sequenced the exonic regions of all eight BLOC-1 subunit-
encoding genes and found a single HPS–8 patient with
a mutation in BLOS3; this patient will be described else-
where. However, we also identified another unique patient
with a nonsense mutation (c.232C>T; p.Gln78Och) in
exon 3 of the pallidin-encoding gene, PLDN (Figure 1A),
and we can thus define a new HPS subtype, HPS-9. The
patient’s mutation was homozygous, despite no known
relationship between the parents. A SNP-chip microarray780 The American Journal of Human Genetics 88, 778–787, June 10,identified homozygosity within the region of the PLDN
locus on chromosome 15q21.1 (Figure 1B), suggesting
distant consanguinity; there was only one other region
of extended homozygosity, on chromosome 6p22.1
(Figure 1C).Clinical Features
The patient, a 9-month-old male of Indian ancestry, pre-
sented at birth with generalized hypopigmentation and
respiratory distress requiring a 3 week admission to a
neonatal intensive-care unit for respiratory support.
Molecular testing for oculocutaneous albinism (OCA)
types 1 and 3 was negative (OCA-1 and OCA-3; MIM
606933 and 203290). Nystagmus, iris transillumination,
and retinal hypopigmentation were noted upon examina-
tion at 3 months (Figure 2A). Upon evaluation at the NIH
Clinical Center at 9 months, platelet electron microscopy
showed absent platelet delta granules, consistent with
HPS (Figure 2B). Growth, development, and general health
were normal, and there was no history of severe or unusual
infections, easy bruising, or bleeding. The irides were pale
blue. Nystagmus was present. No excessive ecchymoses
were observed. Polymorphonuclear leukocyte granules
were morphologically normal. The hair was blond and
silvery (Figure 2A); hair microscopy showed reduced
pigment relative to ethnic background, but no unusual
pigment clumping (Figure 2C). Cultured melanocytes
reflected the reduction in pigment (Figure 2D).PLDN Transcripts
PLDN has two known human mRNA transcripts. Tran-
script 1 contains five coding exons (AF080470), and
transcript 2 has three coding exons (AK128626); only
exon 2 is shared by both transcripts (Figure 3A). Investiga-
tion of the expression pattern of both transcripts across a
variety of adult and fetal tissues (Figure 3B) showed ubiqui-
tous expression of transcript 1, with the notable exception
of both adult and fetal brain, consistent with previous
reports.16,17 In contrast, transcript 2 was expressed only
in adult brain, testis, and leukocytes and in fetal brain,
lung, and thymus.
Our patient’s mutation involves PLDN exon 3, which is
present only in transcript 1, so transcript 2 should not be
affected. Transcript 2 is not expressed in normal fibroblasts
or melanocytes (Figure 3C), and we also demonstrate that
its expression is not upregulated as a compensatory mech-
anism in the patient’s cells (Figure 3C), suggesting that
transcripts 1 and 2 have different promoters and different
functions within cells. Quantitative real-time PCR analysis
of transcript 1 revealed normal PLDNmRNA expression in
the patient’s fibroblasts (97.2% 5 3.8%) and melanocytes
(97.9% 5 4.2%) compared to controls. This finding was
confirmed by the fact that standard PCR with cDNA exclu-
sive primers for transcript 1 gave bands of equal intensity
(Figure 3C). This suggests that nonsense-mediated mRNA
decay is not occurring for this mutation, probably because2011
Figure 1. Molecular Aspects of the HPS-9 Patient
(A) Sequencing chromatograms from control and patient genomic DNA. The patient is homozygous for c.232C>T in exon 3 of PLDN.
(B) SNP-array data for the HPS-9 patient. An enlarged region of the PLDN locus on chromosome 15 shows homozygosity (red bracket)
and the position of the mutation (arrow).
(C) SNP-array data for the HPS-9 patient showing a chromosome 6p22 region that is the only region of extended homozygosity (red
bracket) in his genome. On the B allele plots (upper charts), the middle represents heterozygosity (AB), and the edges represent homo-
zygosity (AA or BB). The log R ratio plots (lower charts) show that there are normal SNP calls in both of these regions, indicating that no
deletions or insertions are present.the mutation is close to (8 bp away from) an intron-exon
boundary.18
Surprisingly, cDNA amplification results showed an
additional weak band in the patient (Figure 3C), suggesting
an alternative splicing event. Although the NetGene2
splice-site prediction tool did not predict additional splice
sites due to the mutation, the Exonic Splicing Enhancers
(ESE) finder tool indicated that c.232C>T would abolish
a SC35 binding site in the DNA; abolishment of this
binding site is predicted to result in the skipping of exon
3.19 Indeed, sequencing of the patient’s additional smaller
PCR band revealed the absence of exon 3, including the
nonsense mutation (Figure 3D). Removal of exon 3
(88 bp) puts exon 4 out of frame, which might introduce
susceptibility to nonsense-mediated decay or create an
alternate protein consisting of 86 amino acids: 74 of the
original pallidin N-terminal amino acids encoded by exons
1 and 2 and then 12 alternate amino acids encoded by
exon 4.The AmeInstability of the BLOC-1 Complex
Despite normal PLDN mRNA expression of transcript 1,
immunoblot analysis showed that pallidin was present in
control fibroblasts but was absent from HPS-9 fibroblasts,
indicating an unstable mutant pallidin protein in the
patient’s cells (Figure 4A). Conversely, pallidin was present
in fibroblasts of HPS patients containing BLOC-2 or BLOC-
3 mutations, suggesting that these complexes assemble
independently of BLOC-1.
Despite the existence of an interactomemap of BLOC-1’s
constituent proteins,20 little is known about the function
of the complex. To address this, we determined the pres-
ence of other members of the BLOC-1 complex with
available antibodies. In the HPS-9 fibroblasts, cappuccino
was absent and snapin was significantly reduced (Fig-
ure 4B), indicating that pallidin is required to stabilize
the BLOC-1 complex.
Pallidin comprises of 172 amino acids and shares no
homology to any known protein. The first 60 aminorican Journal of Human Genetics 88, 778–787, June 10, 2011 781
Figure 2. Clinical Aspects of the HPS-9 Patient
(A) The patient has iris transillumination and fair skin and hair.
(B) Whole-mount electron microscopy of the patient’s platelets revealed no delta granules, which are present in control platelets
(arrows).
(C) Hair shafts show reduced pigmentation in the patient compared to the control, but no abnormal clumping of pigment was seen.
(D) Packed melanocytes show negligible pigment in the HPS-9 patient compared to an ethnically matched control (right panels).acids give rise to an unstructured protein, followed by
two highly a-helical coiled-coil regions (amino acids 60–
100 and 109–172; Figure 4C). The two coiled-coil regions
have been shown to be essential for pallidin to bind
to itself and to syntaxin-13, an early endosomal
t-SNARE.16 Furthermore, syntaxin-13 expression is
reduced in cells of the pallid mouse,16,17 Similarly, our
patient’s melanocytes revealed a weaker-than-normal
signal for syntaxin-13 but normal localization by immu-
nofluorescence microscopy (Figure 4D). Immunoblots
and densitometry showed a 46% reduction in syntaxin-
13 levels in the HPS-9 cells compared to controls (Fig-
ure 4E), indicating that pallidin might be required for
syntaxin-13’s stability, and possibly its correct function,
at least for the syntaxin 13’s cellular portion that associ-
ates with BLOC-1.
To discern the effect of the alternative transcript that
our patient’s mutation creates, we cloned the full-length
PLDN (PLDN-FL) and the alternative transcript with the
splice variant (deleting exon 3; PLDN-D3) into the
pCMV-Myc tag vector. When overexpressed in melano-
cytes, both the PLDN-FL and PLDN-D3 constructs local-
ized to EEA1-positive early endosomes (Figure 4F), as
predicted for BLOC-1 components.15 Expression of the
Myc-PLDN constructs in the HPS-9 patient melanocytes
showed that the PLDN-FL, but not the PLDN-D3
constructs, increased the levels of both cappuccino and
snapin to near normal levels in HPS-9 melanocytes
(Figure 4G). Furthermore, PLDN-FL expression rescued
the amount of pigment in the packed melanocyte pellets
(Figure 4H). Coimmunoprecipitation studies with Myc-
tag antibodies in normal melanocytes showed that
PLDN-FL, but not the PLDN-D3 construct, interacted
with endogenous syntaxin-13 (Figure 4I).782 The American Journal of Human Genetics 88, 778–787, June 10,Defects in Melanin Biogenesis
Another measure of function involves the ability of mela-
nogenic proteins such as tyrosinase, TYRP1 (mutated in
OCA-1 and OCA-3, respectively), and PMEL-17 to traffic
to melanosomes for melanin synthesis.1,10 We observed
a normal, dispersed cytoplasmic distribution of the stage
I and II melanosomemarker PMEL17 in the HPS-9 patient’s
melanocytes (Figure 5A), suggesting correct biogenesis of
these early melanosomal organelles. Early melanosomes
mature into stage III melanosomes by acquiring other mel-
anogenic proteins, such as TYRP1 and tyrosinase, which
are crucial for melanin production, and the eventual result
is melanin-laden stage IV melanosomes required for
pigmentation. This maturation is coupled with the gradual
reduction of PMEL-17 on themelanosomes.We found that
TYRP1 abnormally accumulated in the Golgi region and
occasionally localized to non-Golgi-associated punctate
perinuclear structures and the plasma membrane in HPS-
9 cells (Figure 5B). In contrast, tyrosinase appeared to
partially localize to PMEL-17-labeled structures in the
HPS-9 melanocytes, as in control cells (data not shown),
and did not appear to significantly accumulate in the Golgi
region (Figure 5C), suggesting that the mislocalization in
pallidin-deficient cells is cargo specific. On closer investiga-
tion of the non-Golgi punctate structures of TYRP1, we
found that some of the TYRP1 colocalized with the syn-
taxin-13-positive early endosomes in patient cells only
(Figure 5D), suggesting the mis-sorting of TYRP1 into the
early endosomal compartment.
Previous studies of BLOC-1-deficient mouse melano-
cytes showed enhanced flux of TYRP1 through the plasma
membrane and decreased steady-state TYRP1 levels as
a result of lysosomal degradation of mis-trafficked
TYRP1.15 Our studies of HPS-9 melanocytes yielded similar2011
Figure 3. PLDN mRNA Transcripts
(A) Exon structure of PLDN at the gDNA and mRNA transcript levels. PLDN transcript 1 (PLDN1, encoding 172 amino acids (AA)) and
transcript 2 (PLDN2, encoding 101 AA) have only exon 2 in common. White boxes, untranslated exonic regions; gray boxes, coding
exonic regions; black arrow, position of the HPS-9 patient’s mutation. ‘‘A’’ and ‘‘B’’ represent exons that were identified after the initial
assignment of exon numbers.
(B) PCR amplification shows ubiquitous expression of PLDN1 but a notable absence in both adult and fetal brain. PLDN2 has a more
limited expression pattern. Amplification of GAPDH shows equal loading.
(C) Agarose gel images of fibroblast andmelanocyte cDNA PLDN transcript amplifications. A faint lower band of PLDN1 is detected in the
patient only (arrow). No upregulation of PLDN2 is seen. Loading was controlled by GAPDH.
(D) Sequencing chromatograms of the PLDN1 upper and lower bands from (C) show homozygous presence of the mutation in exon 3 in
the upper band (upper panel, arrow) and complete splicing out of exon 3 in the lower, faint band (lower panel). A dotted line represents
the exon-exon boundary.results: Steady-state TYRP1 levels were decreased in the
patient’s melanocytes by immunofluorescence microscopy
and immunoblotting (Figures 5B and 5E). By biotinylating
the surface proteins before cell lysis, we showed that
TYRP1 was significantly increased in the patient’s plasma
membrane protein fraction (Figure 5E), and the patient’s
melanocytes had a reduced rate of TYRP1 endocytosis in
comparison to that of control cells (Figure 5F).Discussion
Here we report a case of HPS-9 in an infant with albinism
and without platelet delta granules. Our patient had no
clinical signs of additional HPS subtype-specific symp-
toms, such as immunodeficiency, granulomatous colitis,
or pulmonary fibrosis. Some of these symptoms canThe Amedevelop at a later age; therefore, following the clinical
course of this patient as he grows older will be crucial.
Basic studies indicated that our patient exhibited
a homozygous nonsensemutation in PLDN, whose protein
product, pallidin, is a member of the BLOC-1 complex.
This mutation affects only transcript 1 of PLDN, which
has a ubiquitous pattern of expression in adult and fetal
tissues, with the notable exception of both adult and fetal
brain. The strong expression of PLDN transcript 2, coupled
with the absence of transcript 1 in the brain, might reflect
the existence of a neuronal pallidin isoform and suggests
that different promoters for these transcripts might allow
differential tissue expression, such as in the brain. Further-
more, PLDN transcript 2 is not expressed in fibroblasts or
melanocytes and does not become upregulated as a result
of the mutation present in transcript 1 in our patient;
consequently, we speculate that this isoformhas a differentrican Journal of Human Genetics 88, 778–787, June 10, 2011 783
Figure 4. Cellular Studies of HPS-9 Fibroblasts and Melanocytes
(A) Immunoblots of fibroblast extracts of the HPS-9 patient and BLOC-2 and BLOC-3 patients treated with pallidin (BLOC-1), HPS5
(BLOC-2), and HPS4 (BLOC-3) antibodies. Only the HPS-9 patient showed absence of the pallidin protein. The loading control was
b-tubulin.
(B) Immunoblots of control and HPS-9 patient fibroblast lysates treated with antibodies to the BLOC-1 subunits pallidin, cappuccino,
and snapin. Pallidin and cappuccino were undetectable, and snapin was significantly reduced in the HPS-9 patient compared to the
control. Loading was controlled by b-tubulin.
(C) Schematic depiction of the pallidin protein structure. Amino acids 1–60 and 100–109 are unstructured. Highly a-helical and coiled-
coil (CC; gray boxes) regions arewithin amino acids 60–100 and 109–172. TheHPS-9 patient’s p.Gln78Ochmutation is indicated (arrow).
(D) Immunofluorescence images of syntaxin-13 in both control and HPS-9 melanocytes. Syntaxin-13 signal appeared weaker in the
patient than in the control but has the same cellular localization pattern.
(E) An immunoblot with syntaxin-13 antibodies showed reduced expression in the HPS-9 patient compared to the control. Loading was
controlled by b-actin.
(F) Microscopic images of controlmelanocytes transfected withMyc-tagged full-length (PLDN-FL) and the truncated (PLDN-D3) versions
of PLDN showed localization of both to EEA1-positive early endosomes.
(G) Immunoblots of lysates from control and transfected HPS-9 patient melanocytes treated with antibodies to the BLOC-1 subunits pal-
lidin, cappuccino, and snapin. Pallidin, cappuccino, and snapin were returned to near normal levels in only the HPS-9 cells transfected
with the PLDN-FL construct. Loading was controlled by b-tubulin, and expression of the Myc-tag constructs is shown.
(H) Packed melanocytes show negligible pigment in the HPS-9 patient without transfection (see also Figure 3D); only the Myc-PLDN-FL
construct could rescue the production of pigment in the patient’s melanocytes. (I) Coimmunoprecipitation showed that PLDN-FL could
pull down syntaxin-13, but neither the emptyplasmidnor the PLDN-D3version could, despite confirmation that theywere expressed and
synaxin-13 was present in the lysate. A combination of PLDN-FL and PLDN-D3 could also pull down syntaxin-13. For all microscopic
images, nuclei were stained with DAPI (blue); scale bars represent 20 mm.
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Figure 5. Pigment-Biosynthesis Defects in HPS-9
(A) Immunofluorescence images of PMEL-17 in both control and patient melanocytes. A normal dispersed cytoplasmic distribution is
visible in the patient’s cell. PMEL17 is a marker for stage I and II melanosomes, indicating correct biogenesis of these early melanosomal
organelles in the patient’s cells.
(B) Immunofluorescence images of TYRP1 and the Golgi marker TGN38 in control and the HPS-9 patient’s melanocytes. TYRP1 is local-
ized to punctate structures throughout the cytoplasm of control cells. The patient’s cells showed reduced TYRP1 expression and aberrant
TYRP1 localization mainly in the Golgi region (inserts).
(C) Immunofluorescence images of tyrosinase and TGN38. Tyrosinase distribution appeared normal in HPS-9 melanocytes. For the
above microscopy images, nuclei were stained with DAPI (blue); scale bars represent 20 mm.
(D) Enlarged immunofluorescence images of control and HPS-9 melanocytes stained for TYRP1 and syntaxin-13 show occasional coloc-
alization in patient cells only. Scale bars represent 5 mm.
(E) Plasma-membrane protein-biotinylation assay. The HPS-9 patient’s cells showed a significant increase of TYRP1 on the plasma
membrane in comparison to the control. No b-actin was detected in the membrane fraction (demonstrating purity). Whole-cell lysates
showed equal TYRP1 expression in control cells and the HPS-9 patient’s cells (loading was controlled by b-actin).
(F) An TYRP1 internalization assay as a function of time shows a decreased rate of endocytosis from the plasma membrane in the
patient’s melanocytes compared to control cells. Values shown are mean percentages of the initial amount of TYRP1 on the membrane,
and error bars represent51 standard error of the mean (n ¼ 3).function within cells and that this function is potentially
distinct from a role in the BLOC-1 complex. It has
previously been reported that snapin performs an autoph-
agy function in the brain,21 and alterations in dysbindin
have been associated with schizophrenia,22 suggesting
that other BLOC-1 subunits might exhibit dual functions.
Although eight genes encode the BLOC-1 complex and
there are five HPS mouse models with mutations in
BLOC-1 genes,11 only three BLOC-1 human mutations,The Ameincluding those in the patient presented here, have been
identified.7,8 Taken together, the data presented here
suggest that the proteins that constitute the BLOC-1
complex perform varied and essential functions in many
tissue types, potentially as a result of alternative transcripts.
Therefore, mutations in these genes are more than likely to
affect only transcripts that are not essential for develop-
ment and survival in humans, explaining why only a few
mutations have been identified to date. In the case ofrican Journal of Human Genetics 88, 778–787, June 10, 2011 785
pallidin,wemightnever find ahumanwith amutation that
would affect transcript 2 because such amutationmight be
lethal. On the other hand, the failure to identify other
BLOC-1 defects in humans might reflect our ignorance of
the additional functions of BLOC-1 subunits or simply
a redundancy of the proteins performing these functions.
The absence of pallidin in the patient’s melanocytes de-
stabilized other BLOC-1 subunits; decreased syntaxin-13-
BLOC-1 binding; caused mistrafficking of TYRP1, which
accumulated in the Golgi region, the early endosome com-
partment, and cell membrane; and severely reduced
pigment production. The decreased rate of endocytosis of
TYRP1 from the plasma membrane could be due to the
increased amount of TYRP1 present on the membrane,
resulting in saturation of the endocytic recycling
machinery. It is unknown whether the primary trafficking
defect associated with BLOC-1 deficiency is mis-localiza-
tion of TYRP1 to the plasma membrane or to the early en-
dosomal compartment. Increased accumulation of plasma
membrane TYRP1, and the resulting saturated endocytic
recycling machinery, could explain the presence of
TYRP1 in the syntaxin-13-positive early endosomes, sug-
gesting that TYRP1 trafficking to the plasma membrane
is the primary defect. However, it is also possible that
mis-sorting of TYRP1 into syntaxin-13-positive early endo-
somes leads to increased TYRP1 on the cell surface as a
secondary defect.23 We and others15,23 favor the second
hypothesis because disrupting the biosynthetic pathway
by Golgi disruption in BLOC-1-deficient mouse melano-
cytes did not significantly reduce the amount of TYRP1
on the membrane; this suggests the TYRP1 is derived
primarily from the recycling and endosomal compart-
ments.15 Furthermore, the facts that the BLOC-1 complex,
specifically pallidin, interacts with syntaxin-13 and that
cargo are mis-sorted into these syntaxin-13-positive vesi-
cles suggests that the BLOC-1 complex might function to
prevent the delivery of certain proteins to the early endo-
somal compartment. This would allow these proteins to
be properly diverted to melanosomes and other lyso-
some-related organelles, as required.
In many respects, the phenotype of our HPS-9 patient’s
cells resembles that of BLOC-1-deficient mouse melano-
cytes, in which immuno-electron microscopy showed
normal PMEL17 and tyrosinase distribution but TYRP1
accumulation within tubulovesicular structures and early
vacuolar endosomes near the Golgi.15 We conclude that
aberrant TYRP1 trafficking probably contributes to the
hypopigmentation of our patient. However, a more
complete appreciation of the ramifications of pallidin
deficiency awaits the identification and evaluation of
additional HPS-9 patients.Supplemental Data
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